Kegene Biotech Invited to Attend the 2023 7th Future Healthcare 100 Summit
Over the past decade, the global healthcare industry has undergone significant restructuring, a transformation accelerated by the COVID-19 pandemic since 2020. Having withstood the compounded challenges of global upheaval and the century-defining pandemic from 2020 to 2022, 2023 marked the first year for implementing the strategic arrangements outlined at the 20th National Congress of the Communist Party of China, as well as a critical year for advancing the 14th Five-Year Plan. Only by accumulating strength, demonstrating the resilience to “remain steadfast despite countless trials,” and embodying the spirit to “press forward in the face of greater difficulties,” can innovators in the healthcare sector reinforce their confidence through decisive action, thereby delivering a high-quality response to the era’s call for the advanced development of healthcare services.
The 7th Future Healthcare Top 100 Conference, themed “No Boundaries,” was hosted by VCBeat VB100 and Eggshell Research Institute, with strategic cooperation from Shanghai Zhangjiang Group. Integrating cutting-edge academic research insights, comprehensive industry perspectives, and keen capital market trends, the conference was held at the Shanghai Zhangjiang Science Hall from May 5 to 7, 2023. It brought together industry peers to explore the innovative future of the broader health sector and embark on a new journey in healthcare innovation.
After six editions, the conference has become China’s largest and most information-rich ecosystem summit for industry–capital integration in the medical and health innovation sector. Centered on “connecting global wisdom, sharing cutting-edge technologies, inspiring the future of technology, and focusing on venture capital interaction,” it sets the direction for innovation and investment in China’s medical and health field. The 7th Future Healthcare Top 100 Conference in 2023 will feature three flagship summits, more than 20 thematic forums across specialized sectors, release the Future Healthcare Top 100 series rankings and awards, publish more than 10 series reports, and host seven concurrent networking events. It will bring together a diverse array of guests and attendees—including government agencies, academicians and scientists, research and clinical experts, Fortune 500/listed companies, top-tier investment institutions and securities firms, and innovative healthcare enterprises—to convene a gathering of ideas that offers insights to the industry and ushers in a new future.
“Dare to be brave, dare to bloom, ask not of west or east” makes a powerful arrival!
As the life sciences and diagnostics industries continue to experience rapid growth, market demand for high-quality upstream products is increasing. Research reports indicate that the combined global market size for life science tools and in vitro diagnostic (IVD) raw materials has exceeded $100 billion.
The global life sciences sector is flourishing, with increasing convergence among artificial intelligence, big data, and life sciences. Coupled with the implementation of the Biosecurity Law of the People’s Republic of China, the biotechnology industry is poised to encounter unprecedented development opportunities, creating substantial business prospects for life sciences, biotechnology, and their upstream and downstream industries. After nearly three decades of development, and particularly following the rigorous demands of COVID-19 testing, China’s domestic life sciences research tools industry has achieved significant breakthroughs, demonstrating strong momentum for overtaking established competitors.
Among the three major segments of biological reagents, leading enterprises have already emerged in the fields of molecular biology and proteins. In contrast, the cell biology segment has historically been dominated by imported products, with no domestic companies yet going public. KeyGen Biotech aims to leverage its industry expertise to focus on the life sciences cell biology sector. By adopting a strategy of “independent development and proprietary control,” the company is developing more reagent products that match international brands in terms of quality, variety, and efficiency. Whether for research or industrial applications, we maintain strict quality control, establishing R&D, quality assurance, and production systems aligned with industrial-grade standards to meet the growing demand for high-quality scientific research and clinical solutions in China.
Against this backdrop, the 7th Top 100 Conference will feature a dedicated Life Science Tools Forum. The forum will invite industry experts, leading enterprises, and investment institutions to comprehensively discuss current trends in the industry ecosystem from multiple perspectives, centering on the theme of “Localization of Life Science Tools.” It aims to deepen academic exchange and cooperation in the fields of life sciences and healthcare, promote interdisciplinary integration and development, and foster collaboration across upstream and downstream industries. Mr. Sun Yijun, Co-founder and Chairman of GenieBio, will also attend and participate in the roundtable discussion, joining representatives from various sectors of the industry to explore opportunities and challenges, share insights, and discuss ecosystem development.
Conference Time:
May 5–7, 2023
Life Sciences Tools Forum Time:
May 6, 2023
Conference Venue:
Shanghai Zhangjiang Science Hall (No. 1393 Haike Road, Pudong New Area, Shanghai)
Conference Registration:
(Full Conference Pass: Enjoy Access to 30+ Forums)
Kaiji Biotech is a high-tech company dedicated to providing life science tools for cell biology. It has achieved R&D capabilities in cell culture, assay kits, disposable consumables, and various general-purpose instruments and equipment. By offering technical services and comprehensive laboratory solutions, the company strengthens customer engagement and better serves frontline R&D personnel and innovative pharmaceutical and biotechnology firms driving scientific and technological innovation in China.
Kaigi Biotech focuses on the R&D, production, and sales of a full range of cell biology products for life science tools. Its current business includes the sales of reagents, consumables, and instruments for life science tools, as well as providing CRO technical services for preclinical drug screening, cellular, and protein molecular research. Furthermore, the company has established a complete industrial chain layout for clinical diagnostic reagents, with its preeclampsia detection products leading in China.